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Real‑world data of fulvestrant 
as first‑line treatment 
of postmenopausal women 
with estrogen receptor‑positive 
metastatic breast cancer
I. Blancas 1*, C. Olier2, V. Conde3, J. L. Bayo4, C. Herrero5, I. Zarcos‑Pedrinaci6, 
F. Carabantes7, J. M. Baena‑Cañada8, J. Cruz9 & M. Ruiz‑Borrego10
Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, 
maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the 
effectiveness of fulvestrant as first‑line in patients with estrogen receptor (ER)‑positive ABC with 
relapse during or after adjuvant anti‑estrogenic therapy in real‑world settings. Retrospective, 
observational study involving 171 postmenopausal women with ER‑positive ABC who received 
fulvestrant as first‑line between January 2011 and May 2018 in Spanish hospitals. With a median 
follow‑up of 31.4 months, the progression‑free survival (PFS) with fulvestrant was 14.6 months. No 
differences were seen in the visceral metastatic (14.3 months) versus non‑visceral (14.6 months) 
metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%. 
Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with 
ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit 
rate and overall survival than with ECOG 1–2. Results in real‑world settings are in concordance 
with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real‑world 
settings and appears be well tolerated as first‑line for the treatment of postmenopausal women with 
ER‑positive ABC.
Breast cancer (BC) is the most frequent type of carcinoma and leading cause of cancer-related mortality in 
 women1. Incidence and survival rates vary considerably among countries around the world due to diverse fac-
tors such as population structure (age, race, ethnicity), lifestyle, environment, socioeconomic status, genetics, 
disease stage at diagnosis, and healthcare (mammography use, access to high-quality care)2. At diagnosis, most 
of patients present with early BC (EBC), however about 6–10% of cases have distant  metastases3. Furthermore, 
approximately 30% of patients with EBC will develop metastatic BC (MBC) in the following months or  years4. 
The expression of estrogen receptor (ER) and/or the progesterone receptor (PR) are used as prognostic factors 
in patients, and for predicting the response to adjuvant endocrine therapy, the main therapeutic option for ER-
positive advanced breast cancer (ABC)  patients5,6. In this line, ER-positive BC comprise approximately 70% of 
all BC  cases7. Goals of endocrine therapy for ABC include prolonging survival rates, maintaining the quality 
of life, and delaying, as possible, the initiation of  chemotherapy8. Despite the proven efficacy of the endocrine 
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therapy in these patients, one in three cases will develop resistance and, thus, disease  progression9. Recently, 
cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been recommended 
in first- or second-line treatment for patients with ER-positive/HER2-negative  MBC10. However, there are still 
many patients who, due to comorbidities, elderly fragility or in order to avoid an added toxicity, could be suitable 
for receiving only hormonotherapy on this scenario. Thus, it seems relevant to know exactly what to expect from 
fulvestrant in first-line treatment of MBC with real-world data. Fulvestrant is a synthetic, selective ER antagonist 
that triggers the degradation of the ER  protein11. Several phase 3 trials have demonstrated the efficacy and safety 
of fulvestrant, in monotherapy and in combination with other agents, for the treatment of ER-positive ABC. One 
of them is the international FALCON trial that compared the efficacy of fulvestrant with an aromatase inhibitor, 
anastrozole, in 462 ER-positive ABC patients who had not received previously an endocrine  therapy12. Fulvestrant 
showed superior efficacy in terms of progression-free survival (PFS, 16.6 months; 95% confidence interval, 95% 
CI 13.8–21.0 months) than anastrozole (13.8 months, 95% CI 12.0–16.6 months), and similar rates of adverse 
events (AEs). Real-world evidence is an important step for completing data obtained from randomized clinical 
 trials13. Therefore, the objective of the present study was to evaluate the effectiveness of fulvestrant as first-line 
for the treatment of patients with ER-positive MBC with relapse during or after the completion of adjuvant anti-
estrogenic therapy in real-world settings.
Material and methods
This retrospective, observational study involved postmenopausal women with ER-positive ABC who received 
fulvestrant as first-line between January 2011 and May 2018. A total of 11 centers across Spain participated in the 
study. Inclusion criteria were: Informed consent written and signed prior to any specific study of procedures (in 
the case of patients who died at the time of inclusion, there were no signed informed consent, so the researcher 
assumed responsibility for data protection and confidentiality); postmenopausal women, according to NCCN 
definition, i.e. those who underwent a previous bilateral oophorectomy, aged ≥ 60 years, or aged < 60 years and 
amenorrhea for ≥ 12 months in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression, as 
well as follicle-stimulating hormone and  estradiol14; diagnosis of MBC with histological/cytological confirmation; 
positive hormone receptor status (ER-positive and/or PgR-positive) from primary or metastatic tumor tissue 
receptors; Eastern Cooperative Oncology performance status (ECOG PS) score of 0, 1 or 2 at the time of starting 
 fulvestrant15; having experienced recurrence during or after completing the adjuvant anti-estrogenic therapy; 
and receiving fulvestrant 500 mg as first-line, i.e. subsequently to the recurrence. Exclusion criteria included: 
Patients who were not available for the signature date of informed consent (in the case of patients alive at the 
time of study inclusion) or later than the date of baseline study; having received fulvestrant previously; having 
received any other therapy (different to fulvestrant) after the recurrence; previous neoplasia (other than BC or 
treatment for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) unless it has been treated 
curatively with no evidence of disease in the last 5 years; and patients with HER2-positive BC (3-positive HER2 
overexpression by immunohistochemistry or positive gene amplification by fluorescence in situ hybridization 
or similar techniques). The status of ER and PgR was evaluated by using an immunohistochemical analysis 
with antibodies against ER and PgR,  respectively16. The classification of Luminal A and B was also established 
according to immunohistochemistry, i.e. luminal A (ER-positive, PgR-positive, HER2-neagtive, Ki67% ≤ 20), and 
luminal B (other cases)16,17. Patients were followed-up for a minimum period of 12 months were in accordance 
with Declaration of Helsinki and approved by the Ethics Committee of Hospital Universitario San Cecilio (Spain).
Studied variables. The effectiveness of fulvestrant was determined in terms of PFS. The PFS was defined as 
the elapsed time between start of treatment with fulvestrant and disease progression or death, by any cause. Sec-
ondary endpoints included: overall survival (OS), overall response rate (ORR), duration of the response, clinical 
benefit rate (CBR), duration of the clinical benefit (DoCB), response to subsequent treatments, progression-
free rate (PFR), safety, and tolerability. The OS was defined as the elapsed time between start of treatment with 
fulvestrant and death, by any cause. At the time of data collection, data from patients who were alive without 
progression were censored for the survival analysis on the date of their last follow-up. The ORR was calculated 
as the sum of complete response (CR) and partial response (PR); whereas CBR as CR, PR and stable disease 
(SD) persisting for ≥ 24 weeks. The PFR was defined as the proportion of patients who remained with no disease 
progression or death. The AEs were reported by using the Common Terminology Criteria for Adverse Events 
(CTCAE) V4.0. Primary endocrine resistance was defined as the relapse occurrence while on the first 2 years 
of adjuvant endocrine treatment; secondary endocrine resistance as the relapse occurrence while on adjuvant 
endocrine treatment but after the first 2 years; and hormone-sensitive patients as the relapse occurrence after 
1 year of finishing 5 years on adjuvant endocrine treatment.
Statistical analysis. Quantitative variables were expressed as median, interquartile range (IQR) or 95% 
CI; whereas qualitative ones as absolute and relative frequencies. Survival analyses were carried out by follow-
ing Kaplan–Meier methodology. Comparison of survival curves between subgroups was performed using Log-
rank tests. Comparison of variables between subgroups was carried out using parametric (T test or analysis of 
variance, ANOVA), or nonparametric (Mann–Whitney U or Kruskal–Wallis) tests, when appropriate. Statistical 
significance was established when p ≤ 0.05. All statistical procedures were performed using SAS software 9.4.
Ethics approval. Procedures were in accordance with Declaration of Helsinki and approved by the Ethics 
Committee of Hospital Universitario San Cecilio (Spain).
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Consent to participate. All patients signed the informed consent to participate before being included in 
the study.
Results
Study population. A total of 171 patients were recruited in the study; however, 128 fulfilled the inclusion 
criteria. A patient flowchart is shown in Fig. 1. Patients had a median age of 69.2 years (IQR, 59.0–78.9 years) at 
the time of study inclusion. Ductal carcinoma (76.6% of patients) was the most predominant histological type 
of the EBC; predominantly of grade 2 (moderately differentiated, 59.8% of patients). Demographic and clinical 
characteristics of patients are shown in Table 1. At the time of EBC diagnosis, 68.8% of patients were ER-posi-
tive, 78.9% PgR-positive, 68.6% showed a low Ki67 proliferation index (≤ 20%). None of the patients presented 
with de novo metastatic disease. The median time from diagnosis of early disease to ABC was 6.8 years (IQR, 
3.7–10.5 years). Biopsy for metastatic location was performed in 47.7% of patients. A total of 51.6% of patients 
developed metastases in non-visceral locations (41.5% in bones, 10.2% in local relapse). At the time of starting 
treatment with fulvestrant, 93.0% of patients had ECOG PS 0–1. The median duration of the treatment with 
fulvestrant was 14.0 months (IQR, 6.9–26.6 months).
Effectiveness outcomes. With a median follow-up period of 31.4 months, the median PFS with fulves-
trant was 14.6 months (95% CI 10.9–19.9 months; Fig. 2). Effectiveness outcomes considering subgroups of 
patients are shown in Table 2. No differences in PFS were found regarding type of cancer, Ki67 proliferation 
index, ECOG PS at the start of treatment with fulvestrant, metastasis location, adjuvant treatments, and endo-
crine resistance. However, patients ER-positive/ PgR-positive in ABC (on biopsy, median 23.2  months; 95% 
CI 11.5–25.2 months) showed a significant longer PFS than ER-positive /PgR-negative (median 16.1 months; 
95% CI 1.6–21.5 months; p = 0.048). The CBR was 82.8% (95% CI 75.1–88.9%). Significant differences in CBR 
were found regarding: hormone receptors (at EBC; 86.1% for ER-positive/ PgR-positive versus 70.4% for ER-
positive /PgR-negative; p = 0.054); hormone receptors (at ABC, on biopsy; 95.4% for ER-positive / PgR-positive 
versus 53.8% for ER-positive /PgR-negative; p = 0.001); and ECOG PS at the start of treatment (90.9% for ECOG 
0 versus 74.2% for ECOG 1–2; p = 0.012). The median of DoCB with fulvestrant was 19.2  months (95% CI 
14.0–24.1  months). The ORR was 35.2% (95% CI 26.9–44.1%). No significant differences in DoCB or ORR 
were found regarding subgroups (data not shown). The median OS from the start of the fulvestrant treatment 
was 43.1 months (95% CI 35.0–52.3 months; Fig. 3). Patients with ECOG PS 0 at the start of treatment (median 
47.6 months; 95% CI 35.7–70.2 months) showed a significant longer OS than those with ECOG PS 1–2 (median 
36.5 months; 95% CI 26.9–50.1 months; p = 0.024). No differences in OS were found regarding type of cancer, 
hormone receptor, Ki67 proliferation index, metastasis location, adjuvant treatments, and endocrine resistance. 
The PFR was 26.6% (95% CI 19.1–35.1%). No differences in PFR were found regarding subgroups (data not 
shown). A total of 96 patients initiated a subsequent treatment after disease progression with fulvestrant: chemo-
therapy (46 patients, 47.9%); hormonal therapy (46 patients, 47.9%), and radiotherapy (4 patients; 4.2%). After 
this treatment, 78.1% were free of progression: 73.9% in patients with chemotherapy, 75.0% with radiotherapy, 
Figure 1.  Patient flowchart. (a) Informed consent written and signed prior to any specific study of procedures. 
In the case of patients who died at the time of inclusion, there were no signed informed consent, so the 
researcher assumed responsibility for data protection and confidentiality when recording the data; (b) Patients 
who experienced relapse during or after the end of adjuvant anti-estrogenic therapy and received first-line 
treatment with Fulvestrant 500 mg per month during the study period (started treatment with Fulvestrant 
January 1, 2011 to May 30, 2018.
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Patients (N = 128)*
Age at study inclusion, median years (IQR) 69.2 (59.0–78.9)
Early breast cancer
Time from diagnosis to study inclusion, median years (IQR) 11.1 (7.6–15.6)
Histological type, n (%)
Ductal carcinoma 98 (76.6)
Lobular carcinoma 20 (15.6)
Mucinous carcinoma 3 (2.3)
Others 7 (5.5)
Cancer grade, n (%)
N available 117
Grade 1 (Differentiated) 25 (21.4)
Grade 2 (Moderately differentiated) 70 (59.8)
Grade 3 (Poorly differentiated) 22 (18.8)
Hormone receptors, n (%)
ER-positive 88 (68.8)
PgR-positive 101 (78.9)
Ki67 proliferation index, n (%)
N available 121
Low (≤ 20%) 83 (68.6)
High (> 20%) 38 (31.4)
Unknown 7
Type of cancer, n (%)
N available 121
Luminal A 61 (50.4)
Luminal B 60 (49.6)
Unknown 7





Time from diagnosis to study inclusion, median years (IQR) 4.0 (2.5–6.0)
Time from early to advanced disease, median years (IQR) 6.8 (3.7–10.5)





Ki67 proliferation index, n (%)
N available 56
Low (≤ 20%) 33 (58.9)
High (> 20%) 23 (41.1)
Unknown 72
Type of cancer, n (%)
N available 85
Luminal A 41 (48.2)
Luminal B 44 (51.8)
Unknown 43
Metastasis location, n (%)
Visceral 62 (48.4)
Bone 53 (41.4)
Local relapse 13 (10.2)
Previous treatments in the adjuvant setting, n (%)
N available 127
Aromatase inhibitor 74 (58.3)




Scientific Reports |         (2021) 11:4274  | https://doi.org/10.1038/s41598-021-83622-1
www.nature.com/scientificreports/
and 82.6% with hormonal therapy. A total of 42 patients reported a second subsequent treatment: Chemotherapy 
(64.3%), hormonal therapy (26.2%), and radiotherapy (9.5%).
Safety profile. The number of evaluable patients for safety analyses was 139. Of them, 93 patients (66.9%) 
experienced a total of 553 AEs.12 patients (8.6%) reported 14 serious AEs no related with the treatment: res-
piratory/thoracic/mediastinal disorders (4 cases), gastrointestinal disorders (2 cases), hepatobiliary disorders (2 
cases), infections and infestations (2 cases), musculoskeletal and connective tissue disorders (2 cases), injury/
poisoning/procedural complications (1 case), and metabolism and nutrition disorders (1 case). The most preva-
lent AEs were: musculoskeletal and connective tissue disorders (53 patients, 38.1%), asthenia (48, 34.5%), injec-
tion site reactions (30, 21.6%), nausea (18, 12.9%), decreased appetite (18, 12.9%), and diarrhea (15, 10.8%). 
32 AEs (5.8% of the total) were causal relationship: Injection site reaction or hypersensitivity (7); asthenia (7); 
gastrointestinal disorders (6); musculoskeletal and connective tissue disorders (3); blood and lymphatic system 
disorders (2); respiratory- thoracic and mediastinal disorders (2); headache (1); fatigue (1); tachycardia (1); nail 
disorder (1); and decreased appetite (1) (Table 3). One patient died because of a serious AE (grade 5 hemoptysis) 
not related with the fulvestrant.
Table 1.  Demographic and clinical characteristics of patients. IQR interquartile range, EBC early breast cancer, 
ER estrogen receptor, PgR progesterone receptor, ECOG PS Eastern Cooperative Oncology Group performance 
status. *Available n for each variable is 128, unless otherwise indicated. **None of the patients presented with 
de novo metastatic disease. Metastatic information is from the same patients with early breast cancer. ***First 
n (%) for primary endocrine resistance, secondary endocrine resistance and hormone-sensitive patients 
calculated separately; second n (%) for the combination of primary with secondary endocrine resistance, 
and hormone-sensitive patients; and third n (%) for primary endocrine resistance, and the combination of 
secondary endocrine resistance with hormone-sensitive patients.




Time from diagnosis of ABC and start of treatment, median months (IQR) 0.9 (0.3–1.8)




Duration of the treatment, median months (IQR) 14.0 (6.9–26.6)
Endocrine resistance
Primary endocrine resistance, n (%) 24 (18.8), 114 (89.1), and 24 (18.8) ***
Secondary endocrine resistance, n (%) 90 (70.3), 114 (89.1), and 104 (81.2) ***
Hormone-sensitive patients, n (%) 14 (10.9), 14 (10.9), and 104 (81.2) ***
Figure 2.  Progression-free survival from the start of fulvestrant treatment.
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Discussion
The efficacy and safety of fulvestrant is mainly based on results from 3 pivotal randomized clinical  trials12,18–22. 
In the aforementioned phase III FALCON study, involving women who did not receive a previous endocrine 
therapy, the CBR was 78% with fulvestrant and 74% with  anastrozole12. The median DoCB was also numerically 
longer with fulvestrant (22.1 months; 95% CI 18.5–24.9 months versus 19.1 months; 95% CI 16.5–20.5 months)12. 
The OS was not calculated due to insufficient follow-up at the time of data cut-off, however a lower percentage of 
women who died was observed in the fulvestrant group (29%) than with anastrozole (32%). The most frequent 
AE associated to fulvestrant were arthralgia (38 patients, out of 228 evaluable ones for safety, 17%), hot flush 
(26 patients, 11%), fatigue (26 patients, 11%), nausea (24 patients, 11%), and back pain (21 patients, 9%). The 
Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) phase II trial compared the efficacy and 
safety of fulvestrant 500 mg and anastrozole 1 mg as first-line endocrine therapy in 205 postmenopausal women 
with  ABC18–20. With fulvestrant, ORR (36%) and CBR (72.5%) were similar than with anastrozole (35.5% and 
67.0%, respectively). Although the median DoCB had not been reached at primary data cut-off, the tendency 
Table 2.  Efficacy outcomes considering subgroups of patients. EBC early breast cancer, ABC advanced breast 
cancer, ER estrogen receptor, PgR progesterone receptor, ECOG PS Eastern Cooperative Oncology Group 
performance status, N.R. not reached.
Progression-free survival Clinical benefit rate Overall survival
N Median 95% CI p value n (%) p value Median 95% CI p value
Type of cancer (EBC)






Luminal B 60 13.2 7.4–21.5 48 (80.0) 40.0 26.9–58.6
Type of cancer (ABC, on biopsy of the metastasis)






Luminal B 26 16.9 3.4–21.5 20 (76.9) 52.3 23.0–N.R
Hormone receptors (EBC)






ER-positive /PgR-negative 27 10.9 6.8–27.7 19 (70.4) 34.5 20.3–78.0
Hormone receptors (ABC, on biopsy of the metastasis)






ER-positive /PgR-negative 13 16.1 1.6–21.5 7 (53.8) 29.9 16.9–58.6
Ki67 proliferation index (EBC)




High (> 20%) 38 14.3 5.5–24.3 30 (80.0) 43.1 35.0–55.8
Ki67 proliferation index (ABC, on biopsy of the metastasis)






High (> 20%) 23 19.8 5.8–23.6 28 (84.9) 52.3 25.4–N.R
ECOG PS at the start of treatment






1–2 62 14.0 7.7–19.9 46 (74.2) 36.5 26.9–50.1
Metastasis location






Non-visceral 66 14.6 10.2–23.2 57 (86.4) 49.6 35.0–59.1
Previous treatments in the adjuvant setting





0.692Aromatase inhibitor + tamoxifene 27 23.2 12.0–27.4 24 (88.9) 55.8 29.9–70.2
Tamoxifene 26 12.1 6.0–31.8 22 (84.6) 47.4 25.4–58.6
Resistance 1
Primary endocrine resistance 24 12.0 10.0–25.0
0.551
19 (79.2) 31.7 23.9–47.6




Hormone-sensitive patients 14 19.5 6.8–47.9 12 (85.7) 52.0 25.3–74.5
Resistance 2






Hormone-sensitive patients 14 19.5 6.8–47.9 12 (85.7) 52.0 25.3–74.5
Resistance 3






mone-sensitive patients 104 16.9 10.7–23.2 87 (83.7) 47.4 36.5–58.6
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favored fulvestrant, with respect to  anastrozole18. A subsequent follow-up analysis (when 79.5% of patients had 
discontinued the study treatment) revealed a significant longer time to progression with fulvestrant (23.4 months) 
than anastrozole (13.1 months), i.e. 34% reduced the progression  risk19. Moreover, the OS was improved with 
fulvestrant (54.1 months versus 48.4 months with anastrozole)20. Regarding safety, gastrointestinal disturbances 
(28 patients, out of 101 evaluated ones, 27.7%), joint disorders (14 patients, 13.9%), and hot flashes (13 patients, 
12.9%) were the most prevalent AEs related to  fulvestrant18. Finally, the phase III Comparison of Faslodex Recur-
rent or Metastatic Breast Cancer (CONFIRM) trial compared the efficacy and safety of fulvestrant 250 and 500 mg 
in 736 postmenopausal women with  ABC21,22. Fulvestrant 500 mg was used in both first- and second- lines in 
CONFIRM population. The ORR and CBR with fulvestrant 250 mg were 10.2 and 39.6 months, respectively; 
and 9.1 months and 45.6 months with fulvestrant 500 mg21. Fulvestrant 500 mg showed a significant longer PFS 
(6.5 months) versus 250 mg (5.5 months). The median OS was 22.3 and 26.4 months for fulvestrant 250 and 
500 mg,  respectively22. Most prevalent grade ≥ 3 AEs with fulvestrant 250 mg were: joint disorders (8 patients, out 
of 374 evaluable ones, 2.1%), thromboembolic events (4 patients, 1.1%), and ischemic cardiovascular disorders 
(3 patients, 0.8%); whereas with fulvestrant 500 mg were joint disorders (8 patients, out of 361 evaluable, 2.2%), 
and gastrointestinal disturbances (8 patients, 2.2%)21.
Results from our present real-world study are in concordance with pivotal  trials12,18–22: CBR (82.8%, slightly 
higher than 78% in FALCON trial)12, DoCB (19.2 months, slightly reduced than 22.1 months in FALCON 
trial); PFS (14.6 months, similar to 16.6 months in FALCON trial), and OS (43.1 months, slightly reduced than 
54.1 months in FIRST  trial21. The combination of a CDK4/6inhibitor (such as palbociclib, ribociclib or abemaci-
clib) with endocrine therapy is the standard treatment for ER-positive/HER2-negative  MBC10. Recent studies 
have demonstrated that the combination of a CDK4/6 inhibitor and fulvestrant improves OS in patients with 
hormone receptor-positive, HER 2-negative MBC, either after failure of endocrine therapy (and irrespective of 
Figure 3.  Overall survival from the start of fulvestrant treatment.
Table 3.  Incidence of most frequent adverse events.
Adverse event Number of patients (%)
Musculoskeletal and connective tissue disorders 53 (38.1)
Asthenia 48 (34.5)
Injection site reactions 30 (21.6)
Nausea 18 (12.9)




Peripheral neuropathy 11 (7.9)
Palmar-plantar erythrodysesthesia syndrome 11 (7.9)
Vomiting 10 (7.2)




Hot flush 7 (5.0)
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4274  | https://doi.org/10.1038/s41598-021-83622-1
www.nature.com/scientificreports/
menopausal status), and as first- or second-line therapy in postmenopausal  women23,24. Our present study pro-
vides real-world efficacy data from fulvestrant (a high CBR and PFS of 14 months) that can be useful for patients 
who are not candidate for receiving a CDK4/6 inhibitor, due to possible added toxicity of the inhibitor, other 
comorbidities, elderly fragility, or that the patient is not able of undergoing the frequent clinical and hematologic 
controls required for CDK4/6 inhibitors. Indeed, ESMO has recommended for the management of MBC patients 
during the COVID-19 pandemic that, when combining CDK4/6 inhibitors with endocrine therapies, it is needed 
to consider risks of neutropenia, and that the patient requires close monitoring of symptoms of  infection25,26. 
And so, considering the option of postponing a line of CDK4/6 inhibitors, for bone only, low burden, de novo 
metastatic disease, particularly in the elderly. Therefore, nowadays, the results from our study are relevant because 
an important group of patients could benefit from fulvestrant in first-line of MBC treatment.
On the other hand, there are no currently clinical tools that predict which patients may benefit from diverse 
endocrine  therapies27. The CONFIRM and FIRST trials also evaluated PFS according to the characteristics 
of patients; however, the treatment efficacy was consistent across  subgroups19–21. By contrast, FALCON study 
revealed that visceral involvement showed a significant differentiation in PFS (fulvestrant versus anastrozole)12. 
In patients receiving fulvestrant, PFS was 22.3 months (95% CI 16.6–32.8 months) for those with non-visceral 
disease, and 13.8 months (95% CI 11.0–16.5 months) with visceral involvement. In our real-world study, visceral 
disease was not associated with a differential effectiveness of fulvestrant. Nevertheless, ECOG PS 0 at the start 
of treatment was associated with greater CBR and OS, compared with ECOG 1–2.
Regarding the safety profile, reported AEs were in line with observed previously in clinical  trials12,18–22. Most 
frequent AEs included those concerning the musculoskeletal and connective tissue, administration site, and 
gastrointestinal disorders. The AEs did not raise any major concerns. The main limitation of the study derived 
from its retrospective design; providing only available data.
Conclusion
Results in real-world settings are in concordance with previously observed in randomized clinical trials. Moreo-
ver, fulvestrant continues to demonstrate clinical benefits in real-world settings, and appears well tolerated as 
first-line for the treatment of postmenopausal women with ER-positive ABC.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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